Characteristic | Risankizumab (n = 30) | Adalimumab (n = 40) | p-value | Total | |
---|---|---|---|---|---|
Gender | Male, n (%) | 23(76.67) | 22(55.00) | 0.0612 | 45(64.29) |
Female, n (%) | 7(23.33) | 18(45.00) | 25(35.71) | ||
Age (yrs.), mean ± SD | 39.43 ± 15.77 | 32.83 ± 13.12 | 0.0601 | 35.66 ± 14.58 | |
Duration of illness (yrs.), mean ± SD | 6.95 ± 7.97 | 10.50 ± 9.47 | 0.2274 | 9.13 ± 8.19 | |
Duration of therapy (months), mean ± SD | 11.12 ± 5.53 | 26.4 ± 18.66 | < 0.0001 | 19.85 ± 16.37 | |
Weight (KG), mean ± SD | 93.53 ± 32.63 | 80.67 ± 23.20 | 0.0719 | 86.18 ± 28.16 | |
Height (cm), mean ± SD | 168.13 ± 10.02 | 165.91 ± 9.51 | 0.3556 | 166.85 ± 9.72 | |
Body Surface Area (BSA), mean ± SD | 22.71 ± 24.43 | 23.62 ± 23.59 | 0.8842 | 23.28 ± 23.72 | |
PASI score, mean ± SD | 24.78 ± 20.39 | 17.91 ± 12.65 | 0.1109 | 20.86 ± 16.65 | |
Hypertension, n (%) | 5(16.67) | 4(10.00) | 0.4831 | 9(12.86) | |
Diabetes, n (%) | 5(16.67) | 6(15.00) | 1.00 | 11(15.71) | |
Asthma, n (%) | 0(0.0) | 2(5.00) | 0.5031 | 2(2.86) | |
Cardiovascular disease (CVD), n (%) | 2(6.67) | 0(0.0) | 0.1801 | 2(2.86) | |
Dyslipidemia, n (%) | 7(23.33) | 7(17.50) | 0.5460 | 14(20.00) | |
Number of comorbidities, n (%) | 1.13 ± 1.74 | 0.68 ± 1.16 | 0.2173 | 0.87 ± 1.44 |